CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Vitamin Super B-ComplexWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (5)

Name (Synonyms) Correlation
drug1337 Hyperbaric oxygen Wiki 0.58
drug3196 bidirectional oxygenation mouthpiece Wiki 0.58
drug2178 Plaquenil 200Mg Tablet Wiki 0.58
drug1869 Nitazoxanide Wiki 0.55
drug2122 Placebo Wiki 0.09

Correlated MeSH Terms (5)

Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.08
D018352 Coronavirus Infections NIH 0.07
D012128 Respiratory Distress Syndrome, Adult NIH 0.05
D011014 Pneumonia NIH 0.03
D007239 Infection NIH 0.03

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0002090 Pneumonia HPO 0.03

There are 3 clinical trials

Clinical Trials

1 A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)

Trial to evaluate the efficacy and safety of NTZ for post-exposure prophylaxis of COVID-19 and other VRIs in elderly LTCF residents.

NCT04343248 COVID-19 Viral Respiratory Illnesses Drug: Nitazoxanide Drug: Placebo Dietary Supplement: Vitamin Super B-Complex

Primary Outcomes

Description: The proportion of subjects with symptomatic laboratory-confirmed COVID-19 identified after start of treatment and before the end of the 6-week treatment period.

Measure: Symptomatic laboratory-confirmed COVID-19

Time: up to 6 weeks

Description: The proportion of subjects with symptomatic laboratory-confirmed VRI identified after the start of treatment and before the end of the 6-week treatment period.

Measure: Symptomatic laboratory-confirmed VRI

Time: up to 6 weeks

2 A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers

Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers

NCT04359680 COVID-19 Viral Respiratory Illnesses Drug: Nitazoxanide Drug: Placebo Dietary Supplement: Vitamin Super B-Complex

Primary Outcomes

Measure: The proportion of subjects with symptomatic laboratory-confirmed COVID-19 identified after start of treatment and before the end of the 6-week treatment period.

Time: Up to 6 weeks

Measure: The proportion of subjects with symptomatic laboratory-confirmed VRI identified after the start of treatment and before the end of the 6-week treatment period.

Time: Up to 6 weeks

3 Phase 3, Randomized, Double-Blind, Placebo-Controlled, Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19

Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19

NCT04486313 COVID-19 Drug: Nitazoxanide Drug: Placebo Dietary Supplement: Vitamin Super B-Complex

Primary Outcomes

Description: To evaluate the effect of nitazoxanide in reducing the time to sustained response compared to placebo in subjects with mild or moderate COVID-19

Measure: Reducing the Time to Sustained Response

Time: Up to 21 days

Secondary Outcomes

Description: To evaluate the effect of nitazoxanide in reducing the rate of progression to severe COVID-19 illness compared to placebo

Measure: Reducing the Rate of Progression

Time: Up to 21 days

No related HPO nodes (Using clinical trials)